Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DM08XIN)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
EPIANDROSTERONE; 481-29-8; trans-Androsterone; Isoandrosterone; 3Beta-hydroxy-5alpha-androstan-17-one; 3beta-Hydroxyetioallocholan-17-one; epi-andosterone; 5alpha-Androstan-3beta-ol-17-one; iso-Androsterone; d-Epiandrosterone; UNII-8TR252Z538; 3-Epiandrosterone; (3beta,5alpha)-3-hydroxyandrostan-17-one; CHEMBL272195; 3beta-Hydroxy-androstan-17-one; CHEBI:541975; QGXBDMJGAMFCBF-LUJOEAJASA-N; Androsterone, epi-; NSC 93996; MFCD00064134; 8TR252Z538; ST072176; Androstan-17-one, 3-hydroxy-, (3b,5a)-; epi-Androsterone; C19H30O2
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||
